Your AI-Trained Oncology Knowledge Connection!

Video

February 20, 2023

Lifileucel TIL Cell Monotherapy in Patients With Advanced Melanoma After Progression on Immune Checkpoint Inhibitors and Targeted Therapy: Pooled Analysis of Consecutive Cohorts (C-144-01 Study)

Author(s):

Amod Sarnaik, MD, reviews data from a study presented at The Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting on lifileucel tumor-infiltrating lymphocyte [TIL] monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapy.

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

May 2nd 2025 - Jun 7th 2025

online-activity

Video

Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas

May 1st 2025 - Jun 6th 2025

online-activity

Video

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

May 1st 2025 - May 2nd 2026

online-activity

Latest Conference Coverage

Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study

Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

Ultra-Low PSA Response With Darolutamide/ADT Correlates With Better Outcomes in mHSPC

Botensilimab Plus Balstilimab Elicits Durable Responses in Treatment-Refractory HCC

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Lifileucel TIL Cell Monotherapy in Patients With Advanced Melanoma After Progression on Immune Checkpoint Inhibitors and Targeted Therapy: Pooled Analysis of Consecutive Cohorts (C-144-01 Study)

Newsletter

Latest CME

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Community Practice Connections™: Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Community Practice Connections™: Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Community Practice Connections™: Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Latest Conference Coverage